Hype vs. reality: What pharma’s hottest R&D bets have actually proved

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 20 Oct, 12:00 UTC

New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.